David S Schade1, Gayle M Lorenzi2, Barbara H Braffett3, Xiaoyu Gao3, Kathleen E Bainbridge4, Annette Barnie5, Karen J Cruickshanks6, Dayna Dalton6, Lisa Diminick3, Rose Gubitosi-Klug7, John R Kramer8, John M Lachin3, Mary E Larkin9, Catherine C Cowie10. 1. University of New Mexico, Albuquerque, NM dschade@salud.unm.edu. 2. University of California San Diego, La Jolla, CA. 3. Biostatistics Center, George Washington University, Rockville, MD. 4. National Institute on Deafness and Other Communication Disorders, Bethesda, MD. 5. University of Toronto, Toronto, Ontario, Canada. 6. University of Wisconsin-Madison, Madison, WI. 7. Case Western Reserve University, Cleveland, OH. 8. University of Iowa, Iowa City, IA. 9. Massachusetts General Hospital, Boston, MA. 10. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
Abstract
OBJECTIVE: To evaluate the prevalence of hearing impairment in participants with type 1 diabetes enrolled in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study and compare with that of a spousal control group without diabetes. Among participants with type 1 diabetes, to evaluate the association of hearing impairment with prior DCCT therapy and overall glycemia. RESEARCH DESIGN AND METHODS: DCCT/EDIC participants (n = 1,150) and 288 spouses without diabetes were recruited for the DCCT/EDIC Hearing Study. All subjects completed a self-administered questionnaire, medical history, and physical measurements. Audiometry was performed by study-certified personnel; audiograms were assessed centrally. Speech-frequency (pure-tone average [PTA] thresholds at 500, 1,000, 2,000, and 4,000 Hz) and high-frequency impairment (PTA thresholds at 3,000, 4,000, 6,000, and 8,000 Hz) were defined as PTA >25 dB hearing loss. Logistic regression models were adjusted for age and sex. RESULTS: DCCT/EDIC participants and spousal control subjects were similar in age, race, education, smoking, and systolic blood pressure. There were no statistically significant differences between groups in the prevalence or adjusted odds of speech- or high-frequency impairment in either ear. Among participants with type 1 diabetes, for every 10% increase in the time-weighted mean HbA1c, there was a 32% (95% CI 1.15-1.50) and 19% (95% CI 1.07-1.33) increase in speech- and high-frequency hearing impairment, respectively. CONCLUSIONS: We found no significant difference in the prevalence of hearing impairment between the group with type 1 diabetes and the spousal control group. Among those with type 1 diabetes, higher mean HbA1c over time was associated with hearing impairment.
OBJECTIVE: To evaluate the prevalence of hearing impairment in participants with type 1 diabetes enrolled in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study and compare with that of a spousal control group without diabetes. Among participants with type 1 diabetes, to evaluate the association of hearing impairment with prior DCCT therapy and overall glycemia. RESEARCH DESIGN AND METHODS: DCCT/EDIC participants (n = 1,150) and 288 spouses without diabetes were recruited for the DCCT/EDIC Hearing Study. All subjects completed a self-administered questionnaire, medical history, and physical measurements. Audiometry was performed by study-certified personnel; audiograms were assessed centrally. Speech-frequency (pure-tone average [PTA] thresholds at 500, 1,000, 2,000, and 4,000 Hz) and high-frequency impairment (PTA thresholds at 3,000, 4,000, 6,000, and 8,000 Hz) were defined as PTA >25 dB hearing loss. Logistic regression models were adjusted for age and sex. RESULTS:DCCT/EDIC participants and spousal control subjects were similar in age, race, education, smoking, and systolic blood pressure. There were no statistically significant differences between groups in the prevalence or adjusted odds of speech- or high-frequency impairment in either ear. Among participants with type 1 diabetes, for every 10% increase in the time-weighted mean HbA1c, there was a 32% (95% CI 1.15-1.50) and 19% (95% CI 1.07-1.33) increase in speech- and high-frequency hearing impairment, respectively. CONCLUSIONS: We found no significant difference in the prevalence of hearing impairment between the group with type 1 diabetes and the spousal control group. Among those with type 1 diabetes, higher mean HbA1c over time was associated with hearing impairment.
Authors: Karen J Cruickshanks; David M Nondahl; Ted S Tweed; Terry L Wiley; Barbara E K Klein; Ronald Klein; Rick Chappell; Dayna S Dalton; Scott D Nash Journal: Hear Res Date: 2009-10-22 Impact factor: 3.208
Authors: Scott D Nash; Karen J Cruickshanks; Weihai Zhan; Michael Y Tsai; Ronald Klein; Rick Chappell; F Javier Nieto; Barbara E K Klein; Carla R Schubert; Dayna S Dalton; Theodore S Tweed Journal: J Gerontol A Biol Sci Med Sci Date: 2013-06-05 Impact factor: 6.053
Authors: Barbara H Braffett; Gayle M Lorenzi; Catherine C Cowie; Xiaoyu Gao; Kathleen E Bainbridge; Karen J Cruickshanks; John R Kramer; Rose A Gubitosi-Klug; Mary E Larkin; Annette Barnie; John M Lachin; David S Schade Journal: Endocr Pract Date: 2019-08-14 Impact factor: 3.443
Authors: Boris Draznin; Vanita R Aroda; George Bakris; Gretchen Benson; Florence M Brown; RaShaye Freeman; Jennifer Green; Elbert Huang; Diana Isaacs; Scott Kahan; Jose Leon; Sarah K Lyons; Anne L Peters; Priya Prahalad; Jane E B Reusch; Deborah Young-Hyman Journal: Diabetes Care Date: 2022-01-01 Impact factor: 19.112